Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Josh Levine has 25 years of senior-level experience analyzing trends in bio, energy and information technologies and investing in micro- and small-cap stocks. In 2002 he joined independent investment-research boutique ChangeWave Research, where he became editor of ChangeWave MicroCap Investor in 2004. This became Levine's MicroCap Investor in 2010. He is also senior analyst for ChangeWave Research, which manages a survey network comprised of 25,000 members to track the rate of change in corporate and consumer demand trends and provides the results through an institutional research subscription service. ChangeWave is a service of 451 Research, a leading global analyst and data company focused on the business of enterprise IT innovation.
Josh Levine Names Three Biotech Game-Changers (1/3/13) Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor. A second key characteristic is a technology platform that can ultimately generate a suite of products. In this interview with The Life Sciences Report, Levine shares both his investment philosophy and his best three biotech ideas, all of which he expects will return huge multiples to investors.
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >